CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences.

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has revolutionized hematological cancer treatment.
• Variability in CAR T-cell therapy outcomes is not fully explained by antigen choice or patient characteristics.

Purpose of the Study:

• To propose manufacturing platforms as active biological determinants of CAR T-cell therapy outcomes.
• To present a mechanistic framework for understanding how manufacturing influences therapy efficacy, durability, and safety.

Main Methods:

• Review of viral and nonviral manufacturing strategies for CAR T-cell therapy.
• Analysis of a three-layer mechanistic framework: integration biology, clonal fitness, and epigenomic imprinting.
• Examination of clinical observations linking manufacturing platform choice to immune recovery and patient outcomes.

Main Results:

• Viral vectors offer stable integration but face limitations in cost and capacity.
• Nonviral strategies provide faster, cheaper manufacturing with larger payloads but distinct safety/persistence profiles.
• Manufacturing platform choice impacts immune recovery, with implications for infection-related mortality and hematopoietic reserve.

Conclusions:

• Manufacturing processes are integral to CAR T-cell therapy biology and clinical outcomes.
• Decentralized, nonviral production holds potential for democratizing cell therapy and ensuring equitable access.
• Optimizing manufacturing is key to transitioning CAR T-cell therapy from innovation to sustainable global care.